natgillin/translations-raw huggingface dataset:
In Graspa, L-asparaginase is enclosed in red blood cells because it was expected that this would allow the enzyme to work while protecting it from being broken down in blood and from antibodies that may attach to it and stop it from working. 
L-asparaginaza v zdravilu Graspa je vključena v rdeče krvne celice, ker je bilo pričakovano, da bo encim tako lahko učinkoval, hkrati pa bo zaščiten pred razgradnjo v krvi in pred protitelesi, ki bi se lahko pritrdila nanj in tako preprečila njegovo delovanje.
What is Graspa? 
Kaj je zdravilo Graspa?
How does Graspa work? 
Kako zdravilo Graspa deluje?
Giving the enzyme L-asparaginase destroys asparagine in the blood and deprives the leukaemia cells of this amino acid, causing them to die. 
Dajanje encima L-asparaginaze uniči asparagin v krvi in levkemične celice prikrajša za to aminokislino ter jih tako uniči.
Therefore, at the time of the withdrawal, the CHMP was of the opinion that, because of lack of proven effectiveness, the benefits of Graspa did not outweigh its risks. 
Zato je odbor CHMP ob umiku vloge menil, da koristi zdravila Graspa zaradi pomanjkanja dokazov o učinkovitosti ne odtehtajo z njim povezanih tveganj.
Graspa was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 27 October 2006 for ALL. 
Zdravilo Graspa je bilo 27. oktobra 2006 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni) za akutno limfoblastno levkemijo.
Graspa was intended to be given by infusion (drip) into a vein. 
Zdravilo Graspa naj bi se dajalo z infundiranjem (kapalno infuzijo) v veno.
Based on the review of the data, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Graspa could not have been approved for the treatment of ALL. 
Odbor CHMP je na podlagi pregleda podatkov ob umiku vloge izrazil določene zadržke in je začasno menil, da zdravila Graspa ni mogoče odobriti za zdravljenje akutne limfoblastne levkemije.
This summary was last updated in October 2014. 
Povzetek je bil nazadnje posodobljen oktobra 2014.
Mucosal disease is usually fatal. 
Mukozna bolezen je običajno smrtna.
The effectiveness of the vaccine was first studied in a number of laboratory studies in cattle. 
Učinkovitost cepiva so najprej preučevali v več laboratorijskih študijah na govedu.
Protection starts three weeks after vaccination and lasts for one year. 
Zaščita začne učinkovati po treh tednih od cepljenja in traja eno leto.
The European Commission granted a marketing authorisation valid throughout the European Union, for Bovela on 22 December 2014. 
Evropska komisija je dovoljenje za promet z zdravilom Bovela, veljavno po vsej Evropski uniji, odobrila dne 22/12/2014.
Other information about Bovela: 
Druge informacije o zdravilu Bovela:
What benefit has Bovela shown during the studies? 
Kakšne koristi je zdravilo Bovela izkazalo med študijami?
The most common side effect (seen in more than 1 in 100 cattle) was an increase in body temperature (within the normal range) within four hours of vaccination, which spontaneously resolves within 24 hours. 
Najpogostejši neželen učinek (opažen pri več kot 1 od 100 živali) je bilo povišanje telesne temperature (v normalnem razponu) v štirih urah po cepljenju, ki pa je spontano izzvenelo v 24 urah.
However, for the vaccinated group the period of infection was either before vaccination or before the start of protection. 
Vendar pa je v cepljeni skupini do okužbe prišlo bodisi pred cepljenjem bodisi pred začetkom učinkovanja zaščite.
What is the risk associated with Bovela? 
Kakšna tveganja so povezana z zdravilom Bovela?
In the field study 98.5% of vaccinated cattle sampled (range 269-274 animals) developed antibodies to both BVD virus types. 
V terenski študiji je 98,5 % cepljenega goveda, zajetega v vzorec (razpon 269- 274 živali), razvilo protitelesa proti obema tipoma virusa goveje virusne diareje.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Bovela exceed the risks for the approved indication and recommended that Bovela be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Bovela večje od z njim povezanih tveganj za odobreno indikacijo, in priporočil odobritev dovoljenja za promet z zdravilom Bovela.
The purpose of the studies was to establish how long it took for cattle to be fully protected, the length of time protection against BVD lasts, as well as the influence of maternal antibodies (transmitted from the mother) on the effectiveness of the vaccine in calves. 
Namen teh študij je bil ugotoviti, po kolikšnem času je govedo popolnoma zaščiteno, koliko časa traja zaščita pred govejo virusno diarejo in kako maternalna protitelesa (ki se prenašajo z matere na mladiča) vplivajo na učinkovitost cepiva pri teletih.
Bovine viral diarrhoea vaccine (modified live) 
Cepivo proti bovini virusni driski (modificirano živo)
Why has Bovela been approved? 
Zakaj je bilo zdravilo Bovela odobreno?
In the future, if the animals are exposed to the virus the immune system will be able to respond more quickly. 
Ob morebitni ponovni izpostavitvi virusu se bo imunski sistem lahko odzval hitreje.
Bovela is a vaccine. 
Zdravilo Bovela je cepivo.
Bovela is a veterinary vaccine that contains two types of a modified live bovine viral diarrhoea (BVD) virus (BVDV-1 and BVDV-2). 
Zdravilo Bovela je veterinarsko cepivo, ki vsebuje dva tipa modificiranega živega virusa goveje virusne diareje (BVDV-1 in BVDV-2).
The vaccine is given to cattle as a single injection into the muscle. 
Cepivo se govedu daje z enkratno injekcijo v mišico.
The main measure of effectiveness was the reduction in the number of persistently infected newborn calves as determined by virus specific identification tests. 
Glavno merilo učinkovitosti je bilo zmanjšanje števila trajno okuženih novorojenih telet, kar so merili s testi za ugotavljanje prisotnosti posameznega virusa.
In the group vaccinated with Bovela five out of 1,216 (0.4%) newborn calves were persistently infected with the virus, whereas in the group given the dummy injection there were ten persistently infected newborn calves out of 1,183 born (0.8%). 
V skupini, ki je prejela zdravilo Bovela, je bilo pet od 1 216 (0,4 %) novorojenih telet trajno okuženih z virusom, medtem ko je bilo v skupini, ki je prejela injekcijo brez zdravilne učinkovine, deset trajno okuženih novorojenih telet od skupno 1 183 (0,8 %).
It is available as a lyophilisate (freeze dried powder) and solvent for injection. 
Na voljo je v obliki liofilizata (prašek, sušen z zamrzovanjem) in vehikla za injiciranje.
The withdrawal period is the time allowed after administration of the medicine and before the animal can be slaughtered and the meat used for human consumption or milk used for human consumption. 
Karenca je časovno obdobje, ki mora preteči po uporabi zdravila, preden se lahko žival zakolje ter se meso ali mleko uporabi za prehrano ljudi.
To prevent the birth of a PI calf the vaccine should be given at least three weeks before insemination/mating. 
Da bi preprečili kotitev teleta s trajno okužbo, je treba živalim cepivo vbrizgati vsaj tri tedne pred oploditvijo/parjenjem.
Bovela contains two BVDV strains (or types) modified by deletion of parts of two genes so that they can no longer cause disease. 
Zdravilo Bovela vsebuje dva seva oziroma tipa virusa goveje virusne diareje, ki so ga modificirali z izbrisom delov dveh genov, tako da ne more več povzročiti bolezni.
The effectiveness of Bovela was further investigated in the field in eight dairy cattle herds of which five of them had a history of BVD or persistent infection at the beginning of the study. 
Učinkovitost zdravila Bovela so nadalje raziskovali na terenu pri osmih čredah krav molznic, pri čemer so v petih izmed teh čred ob začetku študije že beležili primere okužbe z govejo virusno diarejo ali primere trajne okužbe.
PI animals tend never to reach their productive potential, have reduced fertility and are more susceptible to other diseases. 
Živali s trajno okužbo praviloma nikoli ne dosežejo svojega proizvodnega potenciala, so manj plodne in bolj dovzetne za druge bolezni.
In case of accidental self-injection, medical advice should be sought immediately and the package leaflet or the label shown to the doctor. 
V primeru nenamernega samoinjiciranja takoj poiščite zdravniško pomoč in zdravniku pokažite navodilo za uporabo ali nalepko.
When Bovela is given to cattle the animals' immune system recognises the virus strains as ‘foreign' and makes antibodies against them. 
Ko živali prejmejo zdravilo Bovela, njihov imunski sistem virusna seva prepozna kot „tujka“ in proti njima razvije protitelesa.
What is Bovela used for? 
Za kaj se zdravilo Bovela uporablja?
Approximately half of the cattle were vaccinated with Bovela and the rest received a dummy injection. 
Približno polovica goveda je bila cepljena s cepivom Bovela, ostale živali pa so prejele injekcijo brez zdravilne učinkovine.
This will help protect the cattle against BVD infections. 
To bo pripomoglo k zaščiti goveda pred okužbami z govejo virusno diarejo.
In the laboratory studies Bovela prevented PI in 100% of calves while the animals that received no vaccination gave birth to 100% PI calves. 
V laboratorijskih študijah je zdravilo Bovela preprečilo trajno okužbo pri 100 % telet, medtem ko so krave, ki niso prejele cepiva, skotile 100 % telet s trajno okužbo.
How has Bovela been studied? 
Kako je bilo zdravilo Bovela raziskano?
They may progress to have mucosal disease which is another form of BVD disease with ulcers and blisters on the snout and inside of the mouth. 
Njihova bolezen lahko napreduje v mukozno bolezen, ki je ena od oblik goveje virusne diareje, zaznamujejo pa jo razjede in mehurji na gobcu in v ustih.
In non-pregnant animals the infection is generally mild, with signs affecting the airways such as cough, and reduced milk yield. 
Pri živalih, ki niso breje, je okužba na splošno blaga ter prizadene dihalne poti (kašelj) in zmanjšuje mlečnost.
However a severe form of BVD can occur, when cattle have a high temperature and bloody diarrhoea. 
Pojavi se lahko tudi hujša oblika goveje virusne diareje, zaradi katere ima govedo povišano telesno temperaturo in krvavo drisko.
PI animals are a constant source of BVD virus, infecting other cattle in the herd. 
Živali s trajno okužbo so nenehen vir virusa goveje virusne diareje in tako okužbo prenašajo na drugo govedo v čredi.
Bovela is used to protect cattle against BVD viral infection. 
Zdravilo Bovela se uporablja za zaščito goveda pred okužbo z govejo virusno diarejo.
How does Bovela work? 
Kako zdravilo Bovela deluje?
In pregnant cows, BVD infection can cause abortions or result in the birth of calves that are persistently infected (PI). 
Pri brejih kravah lahko okužba z govejo virusno diarejo povzroči splav ali kotitev telet s trajno okužbo.
The withdrawal period for Bovela for cattle is zero days. 
Karenca za zdravilo Bovela za govedo je nič dni.
What is Bovela? 
Kaj je zdravilo Bovela?
• If you are under 18 years of age. 
• če ste mlajši od 18 let.
Safety and effectiveness in children and adolescents below the age of 18 years have not been established. 
Varnosti in učinkovitosti pri otrocih, mlajših od 18 let, še niso ugotovili.
• Apply the next dose as soon as possible. 
• Nanesite naslednji odmerek takoj, ko je mogoče.
There are no known incompatibilities. 
Ni znanih inkompatibilnosti.
• Are due to complications of diabetes. 
• so posledica zapletov sladkorne bolezni.
• You have any severe or persistently worsening types of cancer 
• imate hudo ali stalno napredujočo vrsto raka,
Use within 6 weeks after first opening. 
Porabite v 6 tednih po prvem odpiranju.
• You have diseases of the arteries. 
• imate bolezen, ki prizadane arterije.
Date opened: 
Datum odpiranja:
If it is almost time for the next application, forget about the missed dose and continue as normal 
Če je že skoraj čas za naslednji nanos, preskočite pozabljeni odmerek in nadaljujte kot normalno.
Date of latest renewal: 19 March 2009 
Datum zadnjega podaljšanja dovoljenja za promet: 19. marec 2009
Detailed information on this medicine is available on the European Medicines Agency (EMEA) website: http://www.emea.europa.eu 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMA) http://www.ema.europa.eu.
Further information 
Dodatni podatki
Refers to erythema at the application site. 
Nanaša se na eritem na mestu aplikacije.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 29 March 1999 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve pridobitve dovoljenja za promet: 29. marec 1999
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR). 
V skladu s smernico CHMP o sistemih za obvladovanje tveganja za zdravila za uporabo v humani medicini mora biti posodobljen RMP predložen hkrati z naslednjim rednim posodobljenim poročilom o varnosti zdravila (PSUR).
Always try to follow the instructions for use exactly. 
Kljub temu pa skušajte vedno natančno upoštevati navodila za uporabo.
These 1883 patients had at least one topical administration of REGRANEX and provided safety data. 
Pri teh 1.883 bolnikih so najmanj enkrat topikalno nanesli zdravilo REGRANEX in posredovali podatke o varnosti.
There are no adequate data from the use of becaplermin in pregnant women. 
Ni zadostnih podatkov o uporabi bekaplermina pri nosečnicah.
• Excessive growth of new tissue at the wound (rare) 
• prekomerno rast novega tkiva v razjedi (redko),
Pregnancy and breast-feeding • Do not use this medicine if you are pregnant, think you might be pregnant or planning to 
Nosečnost in dojenje • Zdravila REGRANEX ne smete uporabljati če ste noseči, mislite, da ste noseči ali nameravate
• If you have or have had cancer 
• če imate ali ste imeli rakavo obolenje,
There are insufficient data to support safe use of the product for more than 20 weeks (see 5.1 Pharmacodynamic properties). 
Podatki, ki bi potrjevali varno uporabo zdravila dlje kot 20 tednov, so nezadostni (glejte poglavje 5.1 Farmakodinamične lastnosti).
REGRANEX 0.01% gel becaplermin 
REGRANEX 0,01 % gel bekaplermin
MARKETING AUTHORISATION NUMBER(S) EU/1/99/101/001 
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET EU/1/99/101/001
Please record the date of opening on the tube label. 
Datum odpiranja vpišite na nalepko na tubi.
REGRANEX is used for skin ulcers that: 
Zdravilo REGRANEX se uporablja pri kožnih razjedah, ki:
• Keeping weight off your feet, perhaps by wearing special orthopaedic shoes or by other methods 
• ukrepe za razbremenitev nog, morda uporabo posebnih ortopedskih čevljev ali druge ukrepe,
Gel in a multidose tube (15 gram). 
Gel v tubi za večkratno odmerjanje (15 gramov).
The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in version 1.0 of the Risk Management Plan (RMP) presented in Module 1.8.2 of the Marketing Authorisation and any subsequent updates of the RMP agreed by the CHMP. 
Imetnik dovoljenja za promet z zdravilom se obvezuje, da bo izvedel študije in dodatne farmakovigilančne aktivnosti, podrobno opisane v načrtu farmakovigilance, sprejetem v različici 1.0 načrta za obvladovanje tveganja (RMP), predloženem v modulu 1.8.2 vloge za pridobitev dovoljenja za promet z zdravilom, in vseh nadaljnjih posodobitvah RMP v soglasju z Odborom za zdravila za uporabo v humani medicini (CHMP).
By using REGRANEX, it is more likely that your skin ulcers will heal quickly and completely. 
Z uporabo zdravila REGRANEX povečamo verjetnost, da se bodo vaše kožne razjede hitro in popolnoma zacelile.
1 year. 
1 leto
Novartis Pharmaceuticals Corporation (Novartis NPC)., 2010 Cessna Drive, Vacaville, CA 95688, USA. 
ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJE Ime in naslov izdelovalca biološke zdravilne učinkovine Novartis Pharmaceuticals Corporation (Novartis NPC)., 2010 Cessna Drive, Vacaville, CA 95688, ZDA.
• If your ulcer is larger than 5 square centimetres (see diagram above) 
• če je razjeda večja od 5 kvadratnih centimetrov (glejte zgornji diagram),
- The tip of the tube should not come into contact with the wound or any other surface. 
- Vrh tube ne sme priti v stik z rano ali katerokoli drugo površino.
It contains a substance called becaplermin. 
Vsebuje učinkovino, ki se imenuje bekaplermin.
• If your ulcer is infected 
• če je razjeda okužena,
Do not use REGRANEX: 
Ne uporabljajte zdravila REGRANEX:
Pharmacotherapeutic group: Preparation for treatment of wounds and ulcers, ATC code: D 03 AX06 
Farmakoterapevtska skupina: Zdravila za oskrbo ran in razjed oznaka ATC: D03AX06
Stop using REGRANEX and tell your doctor straight away if you notice or suspect the following: 
Prenehajte uporabljati zdravilo REGRANEX in se posvetujte z zdravnikom, če opazite ali sumite na:
- The use of a clean application aid is recommended and contact with other parts of the body should be avoided. 
- Priporočamo uporabo čistega pripomočka za nanašanje gela in pri tem se morate izogibati stiku z drugimi deli telesa.
The dressing should be changed at least once a day to keep the wound moist. 
Obkladke menjajte najmanj enkrat na dan, da bo razjeda ves čas vlažna.
• Are not more than 5 square centimetres (see diagram opposite) and have a good blood supply 
• niso večje od 5 kvadratnih centimetrov (glejte diagram spodaj) in so zadostno prekrvavljene
REGRANEX should not be used in patients with ulcers that are not of primarily neuropathic origin, such as those due to arteriopathy or other factors. 
Zdravila REGRANEX ne smete uporabljati pri bolnikih z ulkusi, ki niso primarno nevropatskega izvora, npr. pri ulkusih zaradi arteriopatije ali drugih dejavnikov.
Subjects recruited into these studies were diabetic adults aged 19 years or over who were suffering from at least one stage III or IV diabetic ulcer of at least 8 weeks duration. 
Preiskovanci, ki so jih vključili v ta preskušanja, so bili odrasli bolniki s sladkorno boleznijo, stari 19 let ali več, ki so imeli vsaj po en diabetični ulkus stopnje III ali IV, ki je trajal najmanj 8 tednov.
Do not use this medicine if any of the above apply to you. 
Zdravila Regranex ne smete uporabljati, če za vas velja karkoli od zgoraj navedenega.
• Do not apply a double amount to make up for a missed dose. 
• Ne nanesite dvojne količine gela, da bi nadomestili izpuščeni odmerek.
Treatment with REGRANEX should be initiated and monitored by physicians (specialists or nonspecialists) who are experienced in the management of diabetic wounds. 
Zdravljenje z zdravilom REGRANEX mora uvesti in spremljati zdravnik (specialist ali nespecialist), ki ima izkušnje z zdravljenjem diabetičnih kožnih ulkusov.
Becaplermin was not mutagenic in a battery of in vitro and in vivo tests. 
Bekaplermin ni bil mutagen v seriji in vitro in in vivo testov.
• If you are allergic (hypersensitive) to becaplermin or to any of the other ingredients of 
• če ste alergični (preobčutljivi) na bekaplermin ali katerokoli sestavino zdravila REGRANEX,
REGRANEX should not be used in ulcers of baseline surface area > 5 cm2, or for more than 20 weeks in any individual. 
Zdravila REGRANEX ne smete uporabljati pri ulkusih z začetno površino > 5 cm2 ali dlje kot 20 tednov pri posameznem bolniku.
Clinical absorption studies were conducted in patients with a mean diabetic ulcer area of 10.5 cm² (range 2.3 - 43.5 cm²). 
Klinične študije absorpcije so bile opravljene pri bolnikih s srednjo vrednostjo površine diabetičnega ulkusa 10,5 cm² (razpon od 2,3 do 43,5 cm²).
For cutaneous use only. 
Le za dermalno uporabo.
Like all medicines, REGRANEX can have side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo REGRANEX neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
In animal wound models, the predominant effect of becaplermin is to enhance the formation of granulation tissue. 
V živalskih modelih ran je prevladujoč učinek bekaplermina spodbujanje tvorbe granulacijskega tkiva.
From data combined from 4 clinical trials conducted over a 20 week treatment phase for ulcers of baseline surface area less than or equal to 5 cm2, 47% of ulcers treated with becaplermin 100 μg/g gel completely healed, compared to 35% which were treated with placebo gel alone. 
Na podlagi zbranih podatkov iz 4 kliničnih preskušanj, ki so bila opravljena v 20-tedenski fazi zdravljenja ulkusov z začetno površino manj kot ali enako 5 cm2, se je popolnoma zacelilo 47 % ulkusov, zdravljenih z bekaplerminom v odmerku 100 μg/g gela, v primerjavi s 35 % ulkusov, ki so bili zdravljeni le s placebo gelom.
The name of your medicine is REGRANEX. 
Vaše zdravilo je REGRANEX.
Based on pooled safety data from these clinical trials, the most commonly reported (≥5% incidence) adverse drug reactions (ADRs) were (with % incidence) infected skin ulcer (12.3), cellulitis (10.3), and osteomyelitis (7.2). 
Na osnovi združenih podatkov o varnosti iz teh kliničnih preskušanj, so najpogosteje (pojavnost ≥ 5%) poročali o naslednjih neželenih učinkih (pojavnost v %): okužba kožnega ulkusa (12,3), celulitis (10,3) in osteomielitis (7,2).
Systemic absorption of a single dose and multiple applications for 5 consecutive days of becaplermin to those wounds was insignificant. 
Sistemska absorpcija, pri enkratnem odmerjanju in pri večkratnem odmerjanju bekaplermina na te rane v času 5 zaporednih dni, je bila neznatna.
In view of these data and since becaplermin is a growth factor, Regranex treatment is contraindicated in patients with any known malignancies. 
Zaradi tega in ker je bekaplermin rastni faktor, je zdravilo REGRANEX kontraindicirano pri bolnikih z znano maligno boleznijo.
Preclinical absorption studies through full-thickness wounds were conducted in rats with a wound area of 1.4 - 1.6 cm². 
Predklinična preskušanja absorpcije zdravila skozi rane, ki segajo skozi vso debelino kože, so bila opravljena pri podganah s površino rane od 1,4 do 1,6 cm².
If a wound becomes infected during REGRANEX therapy, the product should be discontinued until the infection has cleared. 
Če se rana okuži med zdravljenjem z zdravilom REGRANEX, je treba zdravljenje prekiniti, dokler se okužba ne pozdravi.
WHAT REGRANEX IS AND WHAT IT IS USED FOR 
KAJ JE ZDRAVILO REGRANEX IN ZA KAJ GA UPORABLJAMO
NAME OF THE MEDICINAL PRODUCT REGRANEX 0.01% gel 
IME ZDRAVILA REGRANEX 0,01 % gel
The safety of REGRANEX Gel was evaluated in 1883 adult patients who participated in 17 clinical trials of REGRANEX and placebo and/or standard therapy (saline dressing). 
Varnost zdravila REGRANEX gel so ocenili pri 1.883 odraslih bolnikih, ki so sodelovali v 17 kliničnih preskušanjih zdravila REGRANEX v primerjavi s placebom in/ali klasičnim zdravljenjem (gaza s fiziološko raztopino).
If during treatment with REGRANEX no meaningful healing progress is evident after the first ten weeks of continuous therapy, treatment should be re-evaluated, and factors known to compromise healing (such as osteomyelitis, ischaemia, infection) should be re-assessed. 
Če med zdravljenjem z zdravilom REGRANEX po prvih 10 tednih neprekinjenega zdravljenja ne opazite bistvenega napredka pri celjenju ulkusa, ponovno ovrednotite zdravljenje in dejavnike, za katere je znano, da slabo vplivajo na celjenje ran (npr. osteomielitis, ishemija, okužbe).
• Redness and pain of skin 
• rdeča in boleča koža.
If your ulcer heals and then returns, do not use REGRANEX again without first checking with your doctor. 
Če se razjeda pozdravi in nato ponovno pojavi, zdravila REGRANEX ne smete začeti uporabljati, ne da bi se pred tem posvetovali z zdravnikom.
You can obtain wooden spatulas from your pharmacist 
Lesene lopatke lahko dobite v lekarni.
The soft tissue adjacent to the injection site had fibroplasia with accompanying mononuclear cell infiltration reflective of the ability of PDGF to stimulate connective tissue growth. 
V mehkih tkivih ob mestu injiciranja so opazili fibroplazijo s spremljajočo infiltracijo mononuklearnih celic, kar kaže na zmožnost PDGF, da spodbudi rast vezivnega tkiva.